References:
Al-Bayaty, F, et al. Evaluation of hyaluronate anti-ulcer activity against gastric mucosal injury. African Journal of Pharmacy and Pharmacology. 5(1): 23-30 (2011).
Balogh, L et al. Absorption, Uptake and Tissue Affinity of High-Molecular-Weight Hyaluronan after Oral Administration in Rats and Dogs. J. Agric. Food Chem. 2008, 56, 10582?10593 (2008).
Bastow, E. et. al. Hyaluronan synthesis and degradation in cartilage and bone. Cellular and Molecular Life Sciences. 65, 395-413 (2008).
Gerdin, B. and Hallgren, R. Dynamic role of hyaluronan in connective tissue activation and inflammation. Journal of Internal Medicine. 242, 49-55 (1997).
Hefner, CS (2012). Oral Hyaluronan Dosage Forms in the Management of Joint Pain. Doctoral Dissertation. Global College of Natural Medicine, Santa Cruz, California. Print.
Kiburz, DW. Evaluation of MHB3® among Patients with Chronic Joint Symptoms. Manuscript in preparation (2006). Lukens W. Unpublished data (2005).
Ma, J and EA Turley. Evaluation of MHB3® on the Development of Osteopenia. In press. (2008).
McIlwraith, C. Use of nutraceuticals for equine joint disease. Current Therapy in Equine Medicine. 94-96 (2009).
Prince, C. Roles of hyaluronan in bone resorption. BMC Musculoskeletal Disorders. 5, 12 (2004).
Sabaratnam, S. et. al. Size selectivity of hyaluronan molecular sieving by extracellular matrix in rabbit synovial joints. The Journal of Physiology. 567, 569-581 (2005).
Seog, J. Direct measurement of glycosaminoglycan intermolecular interactions via high-resolution force spectroscopy. Macromolecules. 35, 5601-5615 (2002).
Spirito, M. Why is HA (hyaluronan) important for joints? Thoroughbred Times. (2011).
Walker, P. et. al. Boosted lubrication in synovial joints by fluid entrapment and enrichment. Annals of the Rheumatic Diseases. 27, 512 (1968).
